Fresenius Kabi Completes Divestment of Its Halden, Norway, Plant

March 1, 2024

Fresenius Kabi and Prange Group have today completed the transfer of ownership of the former Fresenius Kabi plant in Halden, Norway, to HP Halden Pharma AS, a company of the Prange Group. The Prange Group, together with its affiliate Adragos Pharma, took over the plant with equipment and full staff and will continue manufacturing of Fresenius Kabi’s products as agreed in November 2023.

plant in Halden, Norway

In line with Fresenius Kabi’s Vision 2026 strategy, the company announced in May the intention to divest its plant in Halden, Norway. The company expressed the intention of finding a buyer with a relevant and credible business plan for the plant. The company has found the right buyer in the Prange Group in November 2023 due to its proven expertise as B2B contract developer and manufacturer for pharmaceuticals.

“I’m pleased that we have been able to conclude this process and that the Prange Group will now be able to develop the plant and act on their credible and solid business plan,” says Dr. Hans-Christian Meyer, Head of Operations Management Pharma at Fresenius Kabi.

The Prange Group now took over the plant, parts of the equipment, and all employees. The parties have agreed not to share details on the financials of the transaction.

As communicated in November last year, Fresenius Kabi’s Norwegian Market Unit is not affected by the transaction. Fresenius Kabi remains strongly committed to the Norwegian market as it has been since 1999 with the focus on providing high quality products to critically and chronically ill patients.

Prange Group and Adragos Pharma will operate as a contract manufacturing organization for Fresenius Kabi.